Aptevo Therapeutics (NASDAQ:APVO) Issues Earnings Results

Aptevo Therapeutics (NASDAQ:APVO) released its quarterly earnings results on Wednesday. The biotechnology company reported ($6.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($5.60) by ($0.81), Zacks reports.

Aptevo Therapeutics Stock Performance

Shares of Aptevo Therapeutics stock traded down $0.07 during mid-day trading on Wednesday, hitting $4.76. 17,850 shares of the stock were exchanged, compared to its average volume of 129,409. Aptevo Therapeutics has a 12 month low of $3.80 and a 12 month high of $258.01. The company has a 50-day simple moving average of $4.93 and a 200 day simple moving average of $11.89. The company has a market capitalization of $5.62 million, a P/E ratio of 0.00 and a beta of 1.64.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, March 29th. Weiss Ratings upgraded Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Hedge Funds Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new position in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned approximately 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.